Available Technology

Immunogenic Hepatitis E Virus Polypeptides for Vaccine and Diagnostics Development

This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.
Patent Abstract: 
This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.
Benefits 
Generated antibodies were cross-reactive with a number of geographically distinct HEV strains -Useful for development of highly sensitive and specific diagnostic tests -Could be useful for improving efficacy and HEV-strain immunity provided by current vaccine(s)
applications 
Inventors: 
Howard Fields
Patent Number: 
10/257,044
Internal Laboratory Ref #: 
E-152-2013/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin